Logo image
Association between surgeon characteristics and their preferences for guideline-concordant staging and treatment for rectal cancer
Journal article   Peer reviewed

Association between surgeon characteristics and their preferences for guideline-concordant staging and treatment for rectal cancer

Mary E Charlton, Lorren R Mattingly-Wells, Jorge E Marcet, Brenna C McMahon Waldschmidt and John W Cromwell
The American journal of surgery, Vol.208(5), pp.817-823
11/2014
DOI: 10.1016/j.amjsurg.2014.03.010
PMCID: PMC4267050
PMID: 24997492
url
https://www.ncbi.nlm.nih.gov/pmc/articles/4267050View
Open Access

Abstract

Rectal cancer guidelines recommend transrectal ultrasound or magnetic resonance imaging for locoregional staging and neoadjuvant chemoradiation therapy (CRT) for Stage II/III disease, but studies show these are underutilized. We examined how surgeon preferences align with guidelines or vary by training. Questionnaires on training, years of practice, and staging/treatment preferences were sent to surgeons practicing in Florida. Of 759 surveys distributed, 321 (42%) responded; 158 were excluded because they were trainees, not treating rectal cancer, or not board certified/eligible. Among the remaining 163, 71% were general surgeons, 18% colorectal surgeons, and 11% surgical oncologists. Colorectal surgeons and surgical oncologists were more likely than general surgeons to prefer transrectal ultrasound/magnetic resonance imaging (79% vs 50%; P < .01), and neoadjuvant CRT (71% vs 45%; P < .01). Differences remained significant after adjusting for years in practice. Increased focus on appropriate use of staging procedures and neoadjuvant CRT within general surgery training/educational programs is warranted.
Rectal cancer Neoadjuvant therapy Guideline adherence

Details

Metrics

Logo image